Nivolumab & Ipilimumab
ES-2025-027-01
Phase 2 small_molecule active
Quick answer
Nivolumab & Ipilimumab for Lung Cancer - Non Small Cell is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Lung Cancer - Non Small Cell
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active